Legal Representation
Attorney
Frank P. Presta
USPTO Deadlines
Application History
28 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Mar 25, 2019 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED | Loading... |
| Mar 25, 2019 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | Loading... |
| Jul 28, 2018 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Jul 26, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Jul 26, 2018 | EXT3 | S | SOU EXTENSION 3 FILED | Loading... |
| Jul 26, 2018 | EX3G | S | SOU EXTENSION 3 GRANTED | Loading... |
| Feb 17, 2018 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Feb 15, 2018 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Feb 15, 2018 | EXT2 | S | SOU EXTENSION 2 FILED | Loading... |
| Feb 15, 2018 | EX2G | S | SOU EXTENSION 2 GRANTED | Loading... |
| Aug 12, 2017 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | Loading... |
| Aug 10, 2017 | EEXT | I | SOU TEAS EXTENSION RECEIVED | Loading... |
| Aug 10, 2017 | EXT1 | S | SOU EXTENSION 1 FILED | Loading... |
| Aug 10, 2017 | EX1G | S | SOU EXTENSION 1 GRANTED | Loading... |
| Feb 21, 2017 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | Loading... |
| Dec 27, 2016 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Dec 27, 2016 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Dec 7, 2016 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Nov 20, 2016 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Nov 19, 2016 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Nov 18, 2016 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Nov 18, 2016 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| May 20, 2016 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| May 20, 2016 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| May 20, 2016 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| May 15, 2016 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 3, 2016 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Feb 2, 2016 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of Anti-inflammatory, anti-shock, inflammation of digestive system, inflammation of respiratory system, anti-pancreatitis, pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress.; veterinary preparations for Companion animals, farm animals, dogs, cats, horses, chickens, cattle and pigs for the treatment of Anti-inflammatory, anti-shock, inflammation of digestive system, inflammation of respiratory system, anti-pancreatitis, pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress; pharameutical agents affecting digestive organs; pharmaceutical preparations for skin care for animals; medicines for veterinary purposes for Companion animals, farm animals, dogs, cats, horses, chickens, cattle and pigs for the treatment of Anti-inflammatory, anti-shock, inflammation of digestive system, inflammation of respiratory system, anti-pancreatitis, pulmonary insufficiency, kidney disease, disseminated intravascular coagulation, chronic obstructive pulmonary disease, pyometra, spondylosis deformans, systemic inflammatory response syndrome, pneumonia, infectious peritonitis, sepsis, inhibiting thrombogenesis, allergy, tumor metastasis control, infectious disease, encephalitis and surgical stress
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
005